Serveur d'exploration sur la rapamycine et les champignons

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.

Identifieur interne : 001619 ( Main/Exploration ); précédent : 001618; suivant : 001620

Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.

Auteurs : Ling Wang [États-Unis] ; Blossom Damania

Source :

RBID : pubmed:18559509

Descripteurs français

English descriptors

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with three different human malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's disease. The KS lesion is of endothelial cell in origin and is highly dependent on autocrine and paracrine factors for survival and growth. In this study, we show that KSHV infection of endothelial cells induces the activation of the prosurvival phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway. KSHV infection of endothelial cells augmented cell survival in the presence of apoptotic inducers, including etoposide and staurosporine, and under conditions of serum deprivation. We found that KSHV infection of endothelial cells also increased the ability of these cells to form an in vitro tubular network under conditions of stress and growth factor deprivation. Finally, we show that the nuclear factor-kappaB and PI3K pathways are also required for endothelial tubular network formation. Collectively, these results suggest that KSHV infection of endothelial cells modulates cell signaling pathways and induces cell survival and angiogenesis, thereby contributing to the pathogenesis induced by KSHV.

DOI: 10.1158/0008-5472.CAN-07-5988
PubMed: 18559509
PubMed Central: PMC2612117


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.</title>
<author>
<name sortKey="Wang, Ling" sort="Wang, Ling" uniqKey="Wang L" first="Ling" last="Wang">Ling Wang</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
<settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
</affiliation>
</author>
<author>
<name sortKey="Damania, Blossom" sort="Damania, Blossom" uniqKey="Damania B" first="Blossom" last="Damania">Blossom Damania</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18559509</idno>
<idno type="pmid">18559509</idno>
<idno type="doi">10.1158/0008-5472.CAN-07-5988</idno>
<idno type="pmc">PMC2612117</idno>
<idno type="wicri:Area/Main/Corpus">001602</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001602</idno>
<idno type="wicri:Area/Main/Curation">001602</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001602</idno>
<idno type="wicri:Area/Main/Exploration">001602</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.</title>
<author>
<name sortKey="Wang, Ling" sort="Wang, Ling" uniqKey="Wang L" first="Ling" last="Wang">Ling Wang</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</wicri:regionArea>
<placeName>
<region type="state">Caroline du Nord</region>
<settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
</affiliation>
</author>
<author>
<name sortKey="Damania, Blossom" sort="Damania, Blossom" uniqKey="Damania B" first="Blossom" last="Damania">Blossom Damania</name>
</author>
</analytic>
<series>
<title level="j">Cancer research</title>
<idno type="eISSN">1538-7445</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>AMP-Activated Protein Kinases (MeSH)</term>
<term>Antineoplastic Agents, Phytogenic (pharmacology)</term>
<term>Apoptosis (drug effects)</term>
<term>Blotting, Western (MeSH)</term>
<term>Caspase 3 (metabolism)</term>
<term>Cell Survival (physiology)</term>
<term>Cell Transformation, Neoplastic (metabolism)</term>
<term>Cell Transformation, Neoplastic (pathology)</term>
<term>Culture Media, Serum-Free (MeSH)</term>
<term>Endothelium, Vascular (cytology)</term>
<term>Endothelium, Vascular (metabolism)</term>
<term>Endothelium, Vascular (virology)</term>
<term>Enzyme Activation (MeSH)</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Etoposide (pharmacology)</term>
<term>Fibroblast Growth Factor 2 (MeSH)</term>
<term>Herpesvirus 8, Human (physiology)</term>
<term>Humans (MeSH)</term>
<term>Multienzyme Complexes (MeSH)</term>
<term>Phosphatidylinositol 3-Kinases (metabolism)</term>
<term>Poly (ADP-Ribose) Polymerase-1 (MeSH)</term>
<term>Poly(ADP-ribose) Polymerases (metabolism)</term>
<term>Protein Kinases (metabolism)</term>
<term>Protein-Serine-Threonine Kinases (MeSH)</term>
<term>Proto-Oncogene Proteins c-akt (metabolism)</term>
<term>Sarcoma, Kaposi (metabolism)</term>
<term>Sarcoma, Kaposi (pathology)</term>
<term>Sarcoma, Kaposi (virology)</term>
<term>Signal Transduction (MeSH)</term>
<term>Staurosporine (pharmacology)</term>
<term>Survival Rate (MeSH)</term>
<term>TOR Serine-Threonine Kinases (MeSH)</term>
<term>Umbilical Veins (cytology)</term>
<term>Umbilical Veins (metabolism)</term>
<term>Umbilical Veins (virology)</term>
<term>Vascular Endothelial Growth Factor A (MeSH)</term>
<term>Virus Replication (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>AMP-Activated Protein Kinases (MeSH)</term>
<term>Activation enzymatique (MeSH)</term>
<term>Antienzymes (pharmacologie)</term>
<term>Antinéoplasiques d'origine végétale (pharmacologie)</term>
<term>Apoptose (effets des médicaments et des substances chimiques)</term>
<term>Caspase-3 (métabolisme)</term>
<term>Complexes multienzymatiques (MeSH)</term>
<term>Endothélium vasculaire (cytologie)</term>
<term>Endothélium vasculaire (métabolisme)</term>
<term>Endothélium vasculaire (virologie)</term>
<term>Facteur de croissance endothéliale vasculaire de type A (MeSH)</term>
<term>Facteur de croissance fibroblastique de type 2 (MeSH)</term>
<term>Herpèsvirus humain de type 8 (physiologie)</term>
<term>Humains (MeSH)</term>
<term>Milieux de culture sans sérum (MeSH)</term>
<term>Phosphatidylinositol 3-kinases (métabolisme)</term>
<term>Poly (ADP-Ribose) polymerase-1 (MeSH)</term>
<term>Poly(ADP-ribose) polymerases (métabolisme)</term>
<term>Protein kinases (métabolisme)</term>
<term>Protein-Serine-Threonine Kinases (MeSH)</term>
<term>Protéines proto-oncogènes c-akt (métabolisme)</term>
<term>Réplication virale (MeSH)</term>
<term>Sarcome de Kaposi (anatomopathologie)</term>
<term>Sarcome de Kaposi (métabolisme)</term>
<term>Sarcome de Kaposi (virologie)</term>
<term>Staurosporine (pharmacologie)</term>
<term>Survie cellulaire (physiologie)</term>
<term>Sérine-thréonine kinases TOR (MeSH)</term>
<term>Taux de survie (MeSH)</term>
<term>Technique de Western (MeSH)</term>
<term>Transduction du signal (MeSH)</term>
<term>Transformation cellulaire néoplasique (anatomopathologie)</term>
<term>Transformation cellulaire néoplasique (métabolisme)</term>
<term>Veines ombilicales (cytologie)</term>
<term>Veines ombilicales (métabolisme)</term>
<term>Veines ombilicales (virologie)</term>
<term>Étoposide (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Caspase 3</term>
<term>Phosphatidylinositol 3-Kinases</term>
<term>Poly(ADP-ribose) Polymerases</term>
<term>Protein Kinases</term>
<term>Proto-Oncogene Proteins c-akt</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antineoplastic Agents, Phytogenic</term>
<term>Enzyme Inhibitors</term>
<term>Etoposide</term>
<term>Staurosporine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>AMP-Activated Protein Kinases</term>
<term>Culture Media, Serum-Free</term>
<term>Fibroblast Growth Factor 2</term>
<term>Multienzyme Complexes</term>
<term>Poly (ADP-Ribose) Polymerase-1</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>TOR Serine-Threonine Kinases</term>
<term>Vascular Endothelial Growth Factor A</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Sarcome de Kaposi</term>
<term>Transformation cellulaire néoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr">
<term>Endothélium vasculaire</term>
<term>Veines ombilicales</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Endothelium, Vascular</term>
<term>Umbilical Veins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Apoptosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Apoptose</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Cell Transformation, Neoplastic</term>
<term>Endothelium, Vascular</term>
<term>Sarcoma, Kaposi</term>
<term>Umbilical Veins</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Caspase-3</term>
<term>Endothélium vasculaire</term>
<term>Phosphatidylinositol 3-kinases</term>
<term>Poly(ADP-ribose) polymerases</term>
<term>Protein kinases</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Sarcome de Kaposi</term>
<term>Transformation cellulaire néoplasique</term>
<term>Veines ombilicales</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Cell Transformation, Neoplastic</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antienzymes</term>
<term>Antinéoplasiques d'origine végétale</term>
<term>Staurosporine</term>
<term>Étoposide</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Herpèsvirus humain de type 8</term>
<term>Survie cellulaire</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Cell Survival</term>
<term>Herpesvirus 8, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Endothélium vasculaire</term>
<term>Sarcome de Kaposi</term>
<term>Veines ombilicales</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Endothelium, Vascular</term>
<term>Sarcoma, Kaposi</term>
<term>Umbilical Veins</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Blotting, Western</term>
<term>Enzyme Activation</term>
<term>Humans</term>
<term>Signal Transduction</term>
<term>Survival Rate</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>AMP-Activated Protein Kinases</term>
<term>Activation enzymatique</term>
<term>Complexes multienzymatiques</term>
<term>Facteur de croissance endothéliale vasculaire de type A</term>
<term>Facteur de croissance fibroblastique de type 2</term>
<term>Humains</term>
<term>Milieux de culture sans sérum</term>
<term>Poly (ADP-Ribose) polymerase-1</term>
<term>Protein-Serine-Threonine Kinases</term>
<term>Réplication virale</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Taux de survie</term>
<term>Technique de Western</term>
<term>Transduction du signal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with three different human malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's disease. The KS lesion is of endothelial cell in origin and is highly dependent on autocrine and paracrine factors for survival and growth. In this study, we show that KSHV infection of endothelial cells induces the activation of the prosurvival phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway. KSHV infection of endothelial cells augmented cell survival in the presence of apoptotic inducers, including etoposide and staurosporine, and under conditions of serum deprivation. We found that KSHV infection of endothelial cells also increased the ability of these cells to form an in vitro tubular network under conditions of stress and growth factor deprivation. Finally, we show that the nuclear factor-kappaB and PI3K pathways are also required for endothelial tubular network formation. Collectively, these results suggest that KSHV infection of endothelial cells modulates cell signaling pathways and induces cell survival and angiogenesis, thereby contributing to the pathogenesis induced by KSHV.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18559509</PMID>
<DateCompleted>
<Year>2008</Year>
<Month>08</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1538-7445</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>68</Volume>
<Issue>12</Issue>
<PubDate>
<Year>2008</Year>
<Month>Jun</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Cancer research</Title>
<ISOAbbreviation>Cancer Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.</ArticleTitle>
<Pagination>
<MedlinePgn>4640-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/0008-5472.CAN-07-5988</ELocationID>
<Abstract>
<AbstractText>Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with three different human malignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's disease. The KS lesion is of endothelial cell in origin and is highly dependent on autocrine and paracrine factors for survival and growth. In this study, we show that KSHV infection of endothelial cells induces the activation of the prosurvival phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway. KSHV infection of endothelial cells augmented cell survival in the presence of apoptotic inducers, including etoposide and staurosporine, and under conditions of serum deprivation. We found that KSHV infection of endothelial cells also increased the ability of these cells to form an in vitro tubular network under conditions of stress and growth factor deprivation. Finally, we show that the nuclear factor-kappaB and PI3K pathways are also required for endothelial tubular network formation. Collectively, these results suggest that KSHV infection of endothelial cells modulates cell signaling pathways and induces cell survival and angiogenesis, thereby contributing to the pathogenesis induced by KSHV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Ling</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Damania</LastName>
<ForeName>Blossom</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>HL083469</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA096500-06A1</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>CA096500</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL083469-03</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 HL083469</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA096500</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Cancer Res</MedlineTA>
<NlmUniqueID>2984705R</NlmUniqueID>
<ISSNLinking>0008-5472</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009097">Multienzyme Complexes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>103107-01-3</RegistryNumber>
<NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>6PLQ3CP4P3</RegistryNumber>
<NameOfSubstance UI="D005047">Etoposide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="C499320">PARP1 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D000071137">Poly (ADP-Ribose) Polymerase-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.4.2.30</RegistryNumber>
<NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.-</RegistryNumber>
<NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.-</RegistryNumber>
<NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.31</RegistryNumber>
<NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>H88EPA0A3N</RegistryNumber>
<NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016895" MajorTopicYN="N">Culture Media, Serum-Free</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005047" MajorTopicYN="N">Etoposide</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016222" MajorTopicYN="N">Fibroblast Growth Factor 2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019288" MajorTopicYN="N">Herpesvirus 8, Human</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009097" MajorTopicYN="N">Multienzyme Complexes</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000071137" MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014471" MajorTopicYN="N">Umbilical Veins</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18559509</ArticleId>
<ArticleId IdType="pii">68/12/4640</ArticleId>
<ArticleId IdType="doi">10.1158/0008-5472.CAN-07-5988</ArticleId>
<ArticleId IdType="pmc">PMC2612117</ArticleId>
<ArticleId IdType="mid">NIHMS48114</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Cell. 1995 Jun 2;81(5):801-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7774019</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Biol Cell. 2007 Jan;18(1):14-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17065555</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem J. 1999 Dec 1;344 Pt 2:427-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10567225</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 1999 Dec 15;94(12):4247-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10590069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Pharmacol. 2000 Apr;57(4):652-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10727509</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>EMBO J. 2000 Apr 3;19(7):1525-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10747021</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Biol. 2000 Nov 16;10(22):1403-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11102801</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2001 Apr 27;292(5517):727-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11326099</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 2002 Jan;160(1):23-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11786394</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4656-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11904386</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem J. 2002 Jun 1;364(Pt 2):517-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12023895</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2002 Jul 5;297(5578):63-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12098689</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Cell Biol. 2002 Sep;4(9):648-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12172553</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Cell Biol. 2002 Sep;4(9):658-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12172554</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12516034</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2007 Mar 1;109(5):2165-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17082322</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2007 Mar;11(3):245-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17349582</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Opin Investig Drugs. 2007 Apr;16(4):495-504</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17371197</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2007 Apr;81(8):3949-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17287275</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2007 Apr;81(8):3980-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17287278</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2007 Jul;81(13):7001-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17442715</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2003 Feb 7;278(6):3694-704</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12446712</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2003 Feb;3(2):131-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12620408</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Hematol. 2003 Apr;40(2):163-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12704593</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12794189</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2003 Dec 8;22(56):8983-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14663477</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Pharmacol. 2004 Jan 15;67(2):277-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14698040</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2004 Feb;78(4):1918-27</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14747556</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4821-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15047889</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2004 Apr 15;64(8):2774-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15087393</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2004 Aug 1;325(2):225-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15246263</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 2004 Aug 15;18(16):1926-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15314020</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncogene. 2004 Aug 23;23(38):6484-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15322519</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Exp Pathol. 2004 Oct;85(5):233-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15379956</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3457562</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Natl Cancer Inst. 1988 Dec 7;80(19):1526-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2848132</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 1989 Jan 16;158(1):105-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2912441</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Immunol. 1989 Mar;119(1):41-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2784080</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 1995 Aug 15;86(4):1276-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7632932</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1996 May 1;183(5):1957-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8642305</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 1996 Jul 26;271(30):18068-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8663499</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochim Biophys Acta. 1996 Aug 8;1288(1):M11-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8764841</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1997 Jan 31;275(5300):661-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9005851</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1997 Nov 14;91(4):479-89</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9390557</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Genes Dev. 1998 Feb 15;12(4):502-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9472019</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Cell Biol. 1997;75(4):337-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9493956</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 1998 Apr 1;91(7):2475-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9516148</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1998 Jun;152(6):1433-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9626048</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):203-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9665496</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Death Differ. 1999 Feb;6(2):99-104</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10200555</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1999 Aug;19(8):5800-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10409766</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1999 Jul 29;400(6743):464-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10440377</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2004 Dec 16;432(7019):922-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15602565</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Mar 31;352(13):1317-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15800227</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2005 May 15;105(10):3875-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15677565</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Biol Chem. 2005 Sep 16;280(37):32081-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16027121</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 2006 Apr 1;66(7):3658-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16585191</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Cancer. 2006 Aug 15;119(4):757-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16550606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2006 Aug;10(2):133-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16904612</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2006 Nov;80(21):10802-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16956952</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1992 Mar 26;356(6367):356-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1549180</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Res. 1993 Sep 1;53(17):3976-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8358726</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1994 Dec 16;266(5192):1865-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7997879</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 1995 Mar 25;345(8952):761-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7891488</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1995 May 4;332(18):1186-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7700311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Caroline du Nord</li>
</region>
<settlement>
<li>Chapel Hill (Caroline du Nord)</li>
</settlement>
<orgName>
<li>Université de Caroline du Nord à Chapel Hill</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Damania, Blossom" sort="Damania, Blossom" uniqKey="Damania B" first="Blossom" last="Damania">Blossom Damania</name>
</noCountry>
<country name="États-Unis">
<region name="Caroline du Nord">
<name sortKey="Wang, Ling" sort="Wang, Ling" uniqKey="Wang L" first="Ling" last="Wang">Ling Wang</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001619 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001619 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:18559509
   |texte=   Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18559509" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020